Combining two immunotherapies caused tumor rejection in mouse models of pancreatic cancer and provided long-term immune memory that prevented recurrence when tumors were reimplanted in responders months later, researchers MD Anderson report today in Gastroenterology.
The promising combination -- an anti-PD-1 immune checkpoint inhibitor and an antibody that activates the immune-stimulating molecule OX40 – merits further development...
In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...
“Trainees at the Ph.D. and postdoctoral level are leaving the academic research track at alarming rates, and disproportionately if they’re...
Surveying the landscape of T cell presence and activity across the lungs of patients treated for localized non-small cell lung cancer, researchers...
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of ALCL that was first reported in 1996. The U.S....
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a type of cancer treatment in which surgeons apply heated chemotherapy...
While U.S. cervical cancer rates have fallen by 70% since the 1950s thanks to the Pap test and national screening programs, the disease...
Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...